Table 1 Demographics and Characteristics of Pregnant Women Exposed to Sotrovimab (n = 22) for COVID-19 Treatment (Omicron Predominant Era)
n (%) | ||
|---|---|---|
Median Age (years) | 32 | |
Median BMI (kg/m2) | 27 | |
Race/Ethnicity | ||
• Caucasian | 3 (63) | |
• Hispanic | 2 (9) | |
• African-American | 3 (14) | |
• Asian | 2 (9) | |
Co-Morbidities | ||
• Diabetes Mellitus | 2 (9) | |
• Sickle Cell Disease | 2 (9) | |
• HIV | 1 (5) | |
Trimester of sotrovimab receipt | ||
• Trimester 1 | 4 (18) | |
• Trimester 2 | 10 (46) | |
• Trimester 3 | 8 (36) | |
Adverse Events | ||
• Infusion reactions | 0 (0) | |
• Allergic reactions | 0 (0) | |
Monoclonal Antibody Screening Score (MASS) | ||
• < 4 | 22 (100) | |
COVID-19 Vaccination | ||
• Primary series complete | 12 (55) | |
• mRNA-1273 | 5 (46) | |
• BNT162b2 | 5 (46) | |
• JNJ-78,436,735 | 1 (8) | |
• Booster vaccination complete | 0 (0) |